We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
-8.7%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$4.8B
AUM Growth
+$87.7M
Cap. Flow
+$390M
Cap. Flow %
8.12%
Top 10 Hldgs %
41.63%
Holding
117
New
20
Increased
33
Reduced
18
Closed
25

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$187M
2
ISRG icon
Intuitive Surgical
ISRG
+$94.9M
3
HUM icon
Humana
HUM
+$83.2M
4
BIIB icon
Biogen
BIIB
+$79.4M
5
UNH icon
UnitedHealth
UNH
+$65.8M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$123M
2
ARNA
Arena Pharmaceuticals Inc
ARNA
+$113M
3
LLY icon
Eli Lilly
LLY
+$95.2M
4
HOLX
Hologic
HOLX
+$81.5M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$79.1M

Sector Composition

Rank Sector Weight
1 Healthcare 92.34%
2 Miscellaneous 7%
3 Financials 0.49%
4 Technology 0.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNTK icon
1
CALL
State Street SPDR NYSE Technology ETF
XNTK
$2B
$297M 6.18%
+3,300,000
New +$470M
AZN icon
2
AstraZeneca
AZN
$252B
$245M 5.11%
1,850,000
+416,400
+29% +$49.9M
ABBV icon
3
AbbVie
ABBV
$451B
$238M 4.95%
1,466,100
-518,900
-26% -$75.4M
ARVN icon
4
Arvinas
ARVN
$600M
$196M 4.09%
2,915,300
+387,327
+15% +$26.4M
ELV icon
5
Elevance Health
ELV
$85.5B
$196M 4.09%
399,400
+78,400
+24% +$35.8M
MRK icon
6
Merck
MRK
$366B
$194M 4.05%
+2,370,000
New +$187M
AVTR icon
7
Avantor
AVTR
$9.86B
$192M 3.99%
5,668,300
+876,300
+18% +$31.3M
BAX icon
8
Baxter International
BAX
$13.5B
$149M 3.09%
1,915,500
+150,500
+9% +$12.6M
ZNTL icon
9
Zentalis Pharmaceuticals
ZNTL
$360M
$147M 3.05%
3,176,999
+461,999
+17% +$24.9M
BHVN
10
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$146M 3.04%
1,231,000
+91,000
+8% +$11.3M
VRTX icon
11
Vertex Pharmaceuticals
VRTX
$137B
$142M 2.96%
545,600
+265,600
+95% +$63M
UNH icon
12
UnitedHealth
UNH
$353B
$132M 2.76%
259,600
+136,500
+111% +$65.8M
UTHR icon
13
United Therapeutics
UTHR
$22.1B
$129M 2.69%
718,946
+183,946
+34% +$35M
HZNP
14
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$119M 2.48%
1,131,400
+119,400
+12% +$11.6M
MRTX
15
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$115M 2.38%
1,393,000
+586,600
+73% +$60M
ISEE
16
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$109M 2.27%
6,475,400
-479,600
-7% -$7.09M
NBIX icon
17
Neurocrine Biosciences
NBIX
$15.7B
$109M 2.26%
1,160,000
-100,000
-8% -$8.47M
IOVA icon
18
Iovance Biotherapeutics
IOVA
$3.63B
$101M 2.1%
6,043,219
+2,263,219
+60% +$35M
ISRG icon
19
Intuitive Surgical
ISRG
$132B
$98M 2.04%
+325,000
New +$94.9M
CTLT
20
DELISTED
CATALENT, INC.
CTLT
$86.7M 1.81%
782,000
+87,000
+13% +$9.08M
HUM icon
21
Humana
HUM
$46.3B
$86.6M 1.8%
+198,900
New +$83.2M
SNDX icon
22
Syndax Pharmaceuticals
SNDX
$1.74B
$83.8M 1.75%
4,823,400
– –
BIIB icon
23
Biogen
BIIB
$32.3B
$76.9M 1.6%
+365,000
New +$79.4M
RARE icon
24
Ultragenyx Pharmaceutical
RARE
$2.52B
$63.1M 1.31%
869,000
+169,000
+24% +$11.8M
JNJ icon
25
Johnson & Johnson
JNJ
$646B
$62.7M 1.31%
+354,000
New +$60.2M
1
2 3 4 5

Similar funds

DCM
Davidson Capital Management Corpus Christi, Texas $624M AUM 29.17% 1-Year Est. Return
SIG
Spinnaker Investment Group Newport Beach, California $624M AUM 17.54% 1-Year Est. Return
PFA
Pettinga Financial Advisors Evansville, Indiana $624M AUM 24.87% 1-Year Est. Return
ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
CWM
Chemistry Wealth Management New York $625M AUM 19.32% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return

Avidity Partners Management's Q1 2022 Portfolio in Review

As of Q1 2022, Avidity Partners Management held 117 positions worth $4.8B, up 1.9% from $4.71B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Avidity Partners Management deployed $390M of net new capital in Q1 2022, opening 20 new positions and adding to 33 existing holdings. Its largest new stake was Merck: 2,370,000 shares worth $194M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $79.1M trimmed.

  • Avidity Partners Management's largest Q1 2022 buy was Merck: 2,370,000 shares worth $194M.
  • Avidity Partners Management added most to UnitedHealth in Q1 2022, an estimated $65.8M increase.
  • Avidity Partners Management's biggest Q1 2022 reduction was Seagen Inc. Common Stock, cutting an estimated $79.1M.
  • Avidity Partners Management fully exited Pfizer in Q1 2022, selling an estimated $123M.
  • Avidity Partners Management's ten largest holdings make up 42% of its $4.8B portfolio in Q1 2022.
  • Avidity Partners Management opened 20 new positions and closed 25 in Q1 2022.
  • Avidity Partners Management's portfolio value rose 1.9% quarter-over-quarter to $4.8B.

Based on Avidity Partners Management's 13F filing for Q1 2022, filed 16 May 2022.